Trial Profile
A RANDOMIZED, OPEN-LABEL, TWO-PERIOD STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ETANERCEPT ON SKIN AND JOINT DISEASE IN PSORIASIS SUBJECTS WITH PSORIATIC ARTHRITIS
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 01 Feb 2022
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Psoriasis; Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms PRESTA
- Sponsors Pfizer; Wyeth
- 03 Aug 2017 Results of pooled analysis of 10 trials (NCT00245960, NCT00111449, NCT00663052, NCT00454584) generating evidence concerning the number of patients dropping out of etanercept trials published in the British Journal of Dermatology
- 17 Jun 2017 Results of post hoc analysis presented at the 18th Annual Congress of the European League Against Rheumatism
- 13 Jun 2015 Results of post-hoc analysis presented at the 16th Annual Congress of the European League Against Rheumatism.